Q39, a quinoxaline 1,4-Di-N-oxide derivative, inhibits hypoxia-inducible factor-1α expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cells
Q39, a quinoxaline 1,4-Di-N-oxide derivative, inhibits hypoxia-inducible factor-1α expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cells
复制标题
DOI:
10.1007/s10637-010-9462-y
复制
发表时间:
2011-12-01
影响因子:
3.4
通讯作者:
Yang, Bo
中科院分区:
文献类型:
--
作者:
Weng, Qinjie;Zhang, Jun;Yang, Bo
Cumulative evidence has established that hypoxia-inducible factor-1 alpha (HIF-1 alpha) and its downstream target, vascular endothelial growth factor (VEGF), play a critical role in hepatocellular carcinoma angiogenesis, invasiveness and metastasis. 3-(4-bromophenyl)-2-(ethylsulfonyl)-6-methylquinoxaline 1,4-dioxide (Q39) has recently shown great antiproliferative activity in extensive cell lines in normoxia and hypoxia. In this study, Q39 exhibited high antiproliferative activity against hepatoma both in vitro and in vivo, mainly by inducing apoptosis. In addition, suppression of HIF-1 alpha by Q39 resulted in a drastic decrease in VEGF expression. These results indicate that Q39 is an effective inhibitor of HIF-1 alpha and provide new perspectives into the mechanism of its anticancer activity. Interestingly, neither the HIF-1 alpha degradation rate nor the HIF-1 alpha steady-state mRNA level was affected by Q39. Instead, suppression of HIF-1 alpha accumulation by Q39 correlated with prominent dephosphorylation of mTOR and 4E-BP1, a pathway known to regulate protein expression at the translational level.